Skip to main content

Clinical Trials Using Glofitamab

Review the clinical trials studying glofitamab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-17 of 17

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Location: 17 locations
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Status: Active
Location: 15 locations
Testing the Anti-cancer Drug, Glofitamab, in Patients with Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned after CAR-T Cell Therapy
Status: Active
Location: 11 locations
Glofitamab-based Treatment in Older Adults with Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma or Transformed Lymphoma, GLORY Trial
Status: Active
Location: 8 locations
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Status: Active
Location: 7 locations
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 7 locations
Glofitamab and Obinutuzumab with or without Polatuzumab Vedotin, Pirtobrutinib or Atezolizumab for the Treatment Richter's Transformation
Status: Active
Location: 5 locations
Glofitamab with Pirtobrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: 4 locations
Glofitamab with Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients with Newly Diagnosed High Risk Mantle Cell Lymphoma
Status: Active
Location: 3 locations
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Status: Active
Location: 3 locations
Acalabrutinib or Zanubrutinib and Rituximab Followed by Glofitamab and Maintenance Acalabrutinib or Zanubrutinib and Rituximab for the Treatment of High Risk Mantel Cell Lymphoma, WINDOW-4 Trial
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Glofitamab and Axicabtagene Ciloleucel as Second-Line Treatment for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Glofitamab Plus Ibrutinib with Obinutuzumab for the Treatment of Patients with Mantle Cell Lymphoma, IGNITE MCL Trial
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Glofitamab with Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
AMC 120, Glofitamab plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
Status: Active
Location: See ClinicalTrials.gov
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for The Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, REBEL Trial
Status: Approved
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Emapalumab for the Prevention of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients with Relapsed or Refractory Lymphoma and Multiple Myeloma Receiving Bispecific T-Cell Engagers
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York